<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02076711</url>
  </required_header>
  <id_info>
    <org_study_id>201300114731</org_study_id>
    <nct_id>NCT02076711</nct_id>
  </id_info>
  <brief_title>Myocardial Efficiency of the Left Ventricle in Asymptomatic Patients With Aortic Valve Stenosis - a Prognostic Marker and a Target for Intervention?</brief_title>
  <acronym>MELVAS</acronym>
  <official_title>Myocardial Efficiency of the Left Ventricle in Asymptomatic Patients With Aortic Valve Stenosis - a Prognostic Marker and a Target for Intervention?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aarhus University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background - Aortic valve stenosis (AS) is the most common heart valve disease among adults&#xD;
      in the Western world with a prevalence of 3 % in people older than 75 years of age. AS&#xD;
      usually deteriorates over time leading to heart failure, with high mortality if aortic valve&#xD;
      replacement (AVR) is not performed. Thus optimal timing of AVR is crucial, but can be&#xD;
      challenging. Increasing life expectancy in our society will augment the therapeutic and socio&#xD;
      economic impact of AS disease on our health care system. Therefore, new techniques for&#xD;
      monitoring asymptomatic AS patients are needed. A potential approach is monitoring of LV&#xD;
      myocardial efficiency (mechanical work/oxygen consumption). These measures have been&#xD;
      suggested to be involved in the progression of non-valvular heart failure and closely related&#xD;
      to prognosis, but never applied in a larger population of patients with AS. At present there&#xD;
      are no recognized pharmacological treatments of AS. It is known that beta-blocker treatment&#xD;
      in non-valvular systolic heart failure reduce heart rate, improves LV myocardial efficiency&#xD;
      and reduces mortality. However, in patients with AS, the effects of beta-blockers are&#xD;
      unknown.&#xD;
&#xD;
      Hypotheses - Treatment with the beta-blocker metoprolol succinate in patients with&#xD;
      asymptomatic moderate to severe AS has beneficial effects on LV myocardial oxidative&#xD;
      metabolism, myocardial efficiency and contractile function.&#xD;
&#xD;
      Objectives - To investigate if beta-blocker treatment in patients with moderate to severe,&#xD;
      asymptomatic AS has beneficial effects on LV myocardial efficiency, contractile function and&#xD;
      physical performance.&#xD;
&#xD;
      Design - A randomized double blind placebo controlled intervention trial. 40 patients with&#xD;
      asymptomatic AS will be randomized to either per oral metoprolol succinate (N = 20) or&#xD;
      placebo (N= 20) for 22 weeks.&#xD;
&#xD;
      Primary objective - Changes in myocardial efficiency&#xD;
&#xD;
      Secondary objectives - Myocardial oxygen consumption, Myocardial perfusion at rest, LV&#xD;
      myocardial function, LVmass, Aortic valve area and transaortic valve velocities, 6 minute&#xD;
      walking distance, N-terminal prohormone of brain natriuretic peptide, Quality of life&#xD;
      (estimated by Minnesota living with heart failure questionnaire), LV wall stress&#xD;
&#xD;
      Methods - Patients will undergo echocardiography (resting and exercise), [11C]acetate PET and&#xD;
      cardiac magnetic resonance imaging.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LV myocardial efficiency</measure>
    <time_frame>Changes will be evaluated after an expected average of 22 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>LV oxygen consumption</measure>
    <time_frame>Changes will be evaluated after an expected average of 22 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV perfusion</measure>
    <time_frame>Changes will be evaluated after an expected average of 22 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV myocardial function</measure>
    <time_frame>Changes will be evaluated after an expected average of 22 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVmass</measure>
    <time_frame>Changes will be evaluated after an expected average of 22 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aortic valve area</measure>
    <time_frame>Changes will be evaluated after an expected average of 22 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transaortic valve velocities</measure>
    <time_frame>Changes will be evaluated after an expected average of 22 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 minute walking distance</measure>
    <time_frame>Changes will be evaluated after an expected average of 22 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>N-terminal prohormone of brain natriuretic peptide</measure>
    <time_frame>Changes will be evaluated after an expected average of 22 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life - estimated by Minnesota living with heart failure questionnaire</measure>
    <time_frame>Changes will be evaluated after an expected average of 22 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV wall stress</measure>
    <time_frame>Changes will be evaluated after an expected average of 22 weeks of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Aortic Stenosis</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metoprololsuccinate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoprololsuccinate</intervention_name>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aortic valve area ≤1,2 cm2 and/or transaortic maximal velocity (VmaxAO) of 3,0-5,0 m/s&#xD;
&#xD;
          -  Sinus rhythm &gt;60/min after 5 minutes of rest&#xD;
&#xD;
          -  LVEF &gt;≥50%&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  Age 20-100 years old&#xD;
&#xD;
          -  Safe birth control management for women of childbearing potential.&#xD;
&#xD;
          -  Negative urine-HCG for women of childbearing potential&#xD;
&#xD;
          -  Ability to understand the written patient information and to give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Systolic BP &lt;100 mmHg after 5 minutes of rest&#xD;
&#xD;
          -  Left ventricular posterior wall thickness &gt;17 mm&#xD;
&#xD;
          -  Signs or history of major myocardial infarction and/or severe ischemic heart disease&#xD;
&#xD;
          -  Severe asthma or chronic obstructive pulmonary disease&#xD;
&#xD;
          -  New York Heart Association (NYHA) classification &gt; I due to AS&#xD;
&#xD;
          -  NYHA &gt; II due to non-cardiac causes&#xD;
&#xD;
          -  2ᵒ or 3ᵒ atrioventricular block&#xD;
&#xD;
          -  Ongoing beta-blocker therapy&#xD;
&#xD;
          -  Ongoing verapamil or diltiazem therapy&#xD;
&#xD;
          -  Ongoing monoamine oxidase inhibitors therapy (except MAO-B-inhibitors)&#xD;
&#xD;
          -  Sick sinus syndrome&#xD;
&#xD;
          -  Atrial fibrillation or fluttering&#xD;
&#xD;
          -  Lack of stable sinus rhythm&#xD;
&#xD;
          -  Pheochromocytoma&#xD;
&#xD;
          -  Severe peripheral vascular disease&#xD;
&#xD;
          -  Intolerance of Metoprolol succinate or its excipients&#xD;
&#xD;
          -  Other disease or treatment making subject unsuitable for study participation&#xD;
&#xD;
          -  Intolerance of tracer used for [11C]acetate PET recordings&#xD;
&#xD;
          -  Participation in other intervention study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henrik Wiggers, DMSc</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Aarhus University Hospital, Department of Cardiology, Brendstrupgaardsvej 100</name>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>February 27, 2014</study_first_submitted>
  <study_first_submitted_qc>February 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2014</study_first_posted>
  <last_update_submitted>November 10, 2015</last_update_submitted>
  <last_update_submitted_qc>November 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital</investigator_affiliation>
    <investigator_full_name>Henrik Wiggers</investigator_full_name>
    <investigator_title>Senior consultant, Assoc. professor, DMSc</investigator_title>
  </responsible_party>
  <keyword>Aortic Stenosis</keyword>
  <keyword>Myocardial efficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

